Koers Immunovant, Inc. Nasdaq
Aandelen
US45258J2015
Biotechnologie & Medisch Onderzoek
Omzet 2025 * | 564K 526K | Omzet 2026 * | 74,74 mln. 69,78 mln. | Marktkapitalisatie | 3,99 mld. 3,72 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2025 * | -323 mln. -302 mln. | Nettowinst (verlies) 2026 * | -340 mln. -317 mln. | EV/omzet 2025 * | 5.927 x |
Nettoliquiditeiten 2025 * | 644 mln. 601 mln. | Nettoliquiditeiten 2026 * | 612 mln. 572 mln. | EV/omzet 2026 * | 45,1 x |
K/w-verhouding 2025 * |
-12,8
x | K/w-verhouding 2026 * |
-12,8
x | Werknemers | - |
Dividendrendement 2025 * |
-
| Dividendrendement 2026 * |
-
| Vrij verhandelbaar | 42,74% |
Recentste transcriptie over Immunovant, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Peter Salzmann
CEO | Chief Executive Officer | 56 | 01-06-19 |
Eva Barnett
DFI | Director of Finance/CFO | 44 | 04-10-21 |
Sheetal Patel
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 18-12-19 |
Andrew Fromkin
BRD | Director/Board Member | 58 | 18-12-19 |
Douglas Hughes
BRD | Director/Board Member | 62 | 18-12-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+38,36% | 52,5 mld. | |
+36,73% | 39,31 mld. | |
-8,63% | 39,01 mld. | |
+25,46% | 28,2 mld. | |
-11,17% | 26,57 mld. | |
+11,44% | 26,2 mld. | |
+45,09% | 14,15 mld. | |
+32,93% | 12,62 mld. | |
-5,30% | 11,74 mld. |